Caminnov is a biotechnoligical company dedicated to creating new tools and drugs. For detection or therapeutic interest, our research team develop single domain antibodies in two distinct domains: the environment and health. Many VHHs are currently in development and patents have been submitted.
Caminnov specialized in the development of the single domain antibodies against small molecules (peptides, chemical molecules, toxins). In partnership with other team, we have developed VHHs against chemicals molecules present in the environment (MW: 170 g/mol) . In addition, we have developed VHHs against toxins with low molecular weight (MW: 120 g / mol).
Caminnov has developed many VHHs in the field of inflammation (Interleukins…) and receptors (LDL receptor, Transferrin receptor, GPCRs….). The Company has experience in the development of VHHs in the treatment of a wide range of diseases, including inflammation, immuno-oncology and oncology.
Others informations will be soon available.